A new treatment for focal dystonias: IncobotulinumtoxinA (Xeomin®), a botulinum neurotoxin type A free from complexing proteins

Neuropsychiatric Disease and Treatment

Volumn 8, Issue , 2012, Pages 13-25

  Jimenez Shahed, Joohi ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Blepharospasm; Botulinum toxin; Cervical dystonia; Complexing proteins; Dystonia; IncobotulinumtoxinA (Xeomin )

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; HEMAGGLUTININ; HUMAN ALBUMIN; NEUTRALIZING ANTIBODY; PLACEBO; SUCROSE; SYNAPTOBREVIN; SYNAPTOSOMAL ASSOCIATED PROTEIN 25;

ABNORMAL VISION; ANTIBODY PRODUCTION; ARTHRALGIA; ASTHENIA; BACKACHE; BLEPHAROSPASM; BONE PAIN; CERVICAL DYSTONIA; CLOSTRIDIUM BOTULINUM; DEPRESSION; DIARRHEA; DIZZINESS; DRUG DIFFUSION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG STORAGE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPHAGIA; DYSPNEA; ERYTHEMA; FACE EDEMA; FATIGUE; FOCAL DYSTONIA; HEART PALPITATION; HUMAN; IMMUNOGENICITY; LOW DRUG DOSE; MUSCLE ACTION POTENTIAL; MUSCLE WEAKNESS; MYALGIA; NECK PAIN; NONHUMAN; PARESTHESIA; PHOTOPHOBIA; PTOSIS; REVIEW; SINUSITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; XEROPHTHALMIA; XEROSTOMIA;

EID: 84856136132     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. Tarsy D, Simon DK. Dystonia. N Engl J Med. 2006;355(8):818-829.
2. Tanabe LM, Kim CE, Alagem N, Dauer WT. Primary dystonia: molecules and mechanisms. Nat Rev Neurol. 2009;5(11):598-609.
3. Neychev VK, Fan X, Mitev VI, Hess EJ, Jinna HA. The basal ganglia and cerebellum interact in the expression of dystonic movement. Brain. 2008;131(Pt 9):2499-2509.
4. Zoons E, Booij J, Nederveen AJ, Dijk JM, Tijssen MA. Structural, functional and molecular imaging of the brain in primary focal dystonia-A review. Neuroimage. 2011;56(3):1011-1020.
5. Vidailhet M, Grabli D, Roze E. Pathophysiology of dystonia. Curr Opin Neurol. 2009;22(4):406-413.
6. Albanese A, Barnes MP, Bhatia KP, et al. A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS/MDS-ES Task Force. Eur J Neurol. 2006;13(5):433-444.
7. Nutt JG, Muenter MD, Aronson A, Kurland LT, Melton LJ 3rd. Epidemiology of focal and generalized dystonia in Rochester, Minnesota. Mov Disord. 1988;3(3):188-194.
8. Duffey PO, Butler AG, Hawthorne MT, Barnes MP. The epidemiology of the primary dystonias in the north of England. Adv Neurol. 1998;78:121-125.
9. Greene P, Kang UJ, Fahn S. Spread of symptoms in idiopathic torsion dystonia. Mov Disord. 1995;10(2):143-152.
10. Epidemiological Study of Dystonia in Europe (ESDE) Collaborative Group. A prevalence study of primary dystonia in eight European countries. J Neurol. 2000;247(10):787-792.
11. Papantonio AM, Beghi E, Fogli D, et al. Prevalence of primary focal or segmental dystonia in adults in the district of Foggia, southern Italy: a service-based study. Neuroepidemiology. 2009;33(2):117-123.
12. Matsumoto S, Nishimura M, Shibassaki H, Kaji R. Epidemiology of primary dystonias in Japan: comparison with Western countries. Mov Disord. 2003;18(10):1196-1198.
13. Sugawara M, Watanabe S, Toyoshima I. Prevalence of dystonia in Akita Prefecture in Northern Japan. Mov Disord. 2006;21(7):1047-1049.
14. Cossu G, Mereu A, Deriu M, et al. Prevalence of primary blepharospasm in Sardinia, Italy: a service-based survey. Mov Disord. 2006;21(11):2005-2008.
15. Chan J, Brin MF, Fahn S. Idiopathic cervical dystonia: clinical characteristics. Mov Disord. 1991;6(2):119-126.
16. Dauer WT, Burke RE, Greene P, Fahn S. Current concepts on the clinical features, aetiology and management of idiopathic cervical dystonia. Brain. 1998;121(Pt 4):547-560.
17. Jankovic J, Kenney C, Grafe S, Goertelmeyer R, Comes G. Relationship between various clinical outcome assessments in patients with blepharospasm. Mov Disord. 2009;24(3):407-413.
18. Müller J, Kemmler G, Wissel J, et al; Austrian Botulinum Toxin and Dystonia Study Group. The impact of blepharospasm and cervical dystonia on health-related quality of life and depression. J Neurol. 2002;249(7):842-846.
19. Lim VK. Health related quality of life in patients with dystonia and their caregivers in New Zealand and Australia. Mov Disord. 2007;22(7):998-1103.
20. Jankovic J, Leder S, Warner D, Schwartz K. Cervical dystonia: clinical findings and associated movement disorders. Neurology. 1991;41(7):1088-1091.
21. Grandas F, Elston J, Quinn N, Marsden CD. Blepharospasm: a review of 264 patients. J Neurol Neurosurg Psychiatry. 1988;51(6):767-772.
22. Jankovic J, Havins WE, Wilkins RB. Blinking and blepharospasm. Mechanism, diagnosis, and management. JAMA. 1982;248(23):3160-3164.
23. Martino D, Liuzzi D, Macerollo A, Aniello MS, Livrea P, Defazio G. The phenomenology of the geste antagoniste in primary blepharospasm and cervical dystonia. Mov Disord. 2010;25(4):407-412.
24. O'Riordan S, Raymond D, Lynch T, et al. Age at onset as a factor in determining the phenotype of primary torsion dystonia. Neurology. 2004;63(8):1423-1426.
25. Defazio G, Berardelli A, Hallett M. Do primary adult-onset focal dystonias share aetiological factors? Brain. 2007;130(Pt 5):1183-1193.
26. Haussermann P, Marczoch S, Klinger C, Landgrebe M, Conrad B, Ceballos-Bauman A. Long-term follow-up of cervical dystonia patients treated with botulinum toxin A. Mov Disord. 2004;19(3):303-308.
27. Weiss EM, Hershey T, Karimi M, et al. Relative risk of spread of symptoms among the focal onset primary dystonias. Mov Disord. 2006;21(8):1175-1181.
28. Hierholzer J, Cordes M, Schelosky L, et al. Dopamine D2 receptor imaging with iodine-123-iodobenzamide SPECT in idiopathic rotational torticollis. J Nucl Med. 1994;35(12):1921-1927.
29. Perlmutter JS, Stambuk MK, Markham J, et al. Decreased [18F] spiperone binding in putamen in idiopathic focal dystonia. J Neurosci. 1997;17(2):843-850.
30. Naumann M, Pirker W, Reiners K, Lange KW, Becker G, Brücke T. Imaging the pre-and postsynaptic side of striatal dopaminergic synapses in idiopathic cervical dystonia: a SPECT study using [123I] epidepride and [123I] beta-CIT. Mov Disord. 1998;13(2):319-323.
31. Karimi M, Moerlein SM, Videen TO, et al. Decreased striatal dopamine receptor binding in primary focal dystonia: a D2 or D3 defect? Mov Disord. 2011;26(1):100-106.
32. Pauletti G, Berardelli A, Cruccu G, Agostino R, Manfredi M. Blink reflex and the masseter inhibitory reflex in patients with dystonia. Mov Disord. 1993;8(4):495-500.
33. Tolosa E, Montserrat L, Bayes A. Blink reflex studies in focal dystonias: enhanced excitability of brainstem interneurons in cranial dystonia and spasmodic torticollis. Mov Disord. 1988;3(1):61-69.
34. Berardelli A, Rothwell JC, Day BL, Marsden CD. Pathophysiology of blepharospasm and oromandibular dystonia. Brain. 1985;108(Pt 3):593-608.
35. Rinnerthaler M, Benecke C, Bartha L, Entner T, Poewe W, Mueller J. Facial recognition in primary focal dystonia. Mov Disord. 2006;21(1):78-82.
36. Molloy FM, Carr TD, Zeuner KE, Dambrosia JM, Hallett M. Abnormalities of spatial discrimination in focal and generalized dystonia. Brain. 2003;126(Pt 10):2175-2182.
37. Obermann M, Yaldizli O, De Greiff A, et al. Morphometric changes of sensorimotor structures in focal dystonia. Mov Disord. 2007;22(8):1117-1123.
38. Albanese A, Asmus F, Bhatia KP, et al. EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol. 2011;18(1):5-18.
39. Simpson DM, Blitzer A, Brashear A, et al; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70(19):1699-1706.
40. Jankovic J. Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry. 2004;75(7):951-957.
41. Adam OR, Jankovic J. Treatment of dystonia. Parkinsonism Relat Disord. 2007;13(Suppl 3):S362-S368.
42. Albanese A. Terminology for preparations of botulinum toxins: what a difference a name makes. JAMA. 2011;305(1):89-90.
43. Wenzel R, Jones D, Borrego JA. Comparing two botulinum toxin type A formulations using manufacturers' product summaries. J Clin Pharm Ther. 2007;32(4):387-402.
44. Comella C, Jankovic J, Shannon KM, et al; Dystonia Study Group. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology. 2005;65(9):1423-1429.
45. Pappert EJ, Germanson T; Myobloc/Neurobloc European Cervical Dystonia Study Group. Botulinum toxin type B vs type A in toxinnaïve patients with cervical dystonia: randomized, double-blind, noninferiority trial. Mov Disord. 2008;23(4):510-517.
46. Hallett M, Benecke R, Blitzer A, Comella CL. Treatment of focal dystonias with botulinum neurotoxin. Toxicon. 2009;54(5):628-633.
47. Sampaio C, Ferreira JJ, Simões F, et al. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A-Dysport and Botox-assuming a ratio of 4:1. Mov Disord. 1997;12(6):1013-1018.
48. Odergren T, Hjaltason H, Kaakkola S, et al. A double-blind, randomised, parallel group study to investigate the dose equivalence of Dysport® and Botox® in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry. 1998;64(1):6-12.
49. Ranoux D, Gury C, Fondarai J, Mas JL, Zuber M. Respective potencies of Botox and Dysport: a double-blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry. 2002;72(4):459-462.
50. Nüssgens Z, Roggenkämper P. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Ophthalmol. 1997;235(4):197-199.
51. Benecke R, Jost WH, Kanovsky P, Ruzicka E, Comes G, Grafe S. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology. 2005;64(11):1949-1951.
52. Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology. 2003;60(7):1186-1188.
53. Dressler D, Hallett M. Immunological aspects of Botox®, Dysport® and Myobloc™/Neurobloc®. Eur J Neurol. 2006;13 Suppl 1:11-15.
54. Dressler D, Bigalke H. Botulinum toxin type B de novo therapy of cervical dystonia: frequency of antibody induced therapy failure. J Neurol. 2005;252(8):904-907.
55. Brin MF, Comella CL, Jankovic J, Lai F, Naumann M; CD-017 BoNTA Study Group. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord. 2008;23(10):1353-1360.
56. Dressler D, Bigalke H, Benecke R. Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure. J Neurol. 2003;250(8):967-969.
57. Frevert J, Dressler D. Complexing proteins in botulinum toxin type A drugs: a help or a hindrance? Biologics. 2010;4:325-332.
58. Hauser D, Eklund MW, Boquet P, Popoff MR. Organization of the botulinum neurotoxin C1 gene and its associated non-toxic protein genes in Clostridium botulinum C 468. Mol Gen Genet. 1994;243(6):631-640.
59. Minton NP. Molecular genetics of clostridial neurotoxins. Curr Top Microbiol Immunol. 1995;195:161-194.
60. Ohishi I, Sugii S, Sakaguchi G. Oral toxicities of Clostridium botulinum toxins in response to molecular size. Infect Immun. 1977;16(1):107-109.
61. Ohishi I, Sakaguchi G. Oral toxicities of Clostridium botulinum type C and D toxins of different molecular sizes. Infect Immun. 1980;28(2):303-309.
62. Aoki KR, Ranoux D, Wissel J. Using translational medicine to understand clinical differences between botulinum toxin formulations. Eur J Neurol. 2006;13 Suppl 4:10-19.
63. Zhou Y, Foss S, Lindo P, Sarkar H, Singh BR. Hemagglutinin-33 of type A botulinum neurotoxin complex binds with synaptotagmin II. FEBS J. 2005;272(11):2717-2726.
64. Eisele KH, Fink K, Vey M, Taylor HV. Studies on the dissociation of botulinum toxin type A complexes. Toxicon. 2011;57(4):555-565.
65. Frevert J. Xeomin is free from complexing proteins. Toxicon. 2009;54(5):697-701.
66. Panjwani N, O'Keefe R, Pickett A. Biochemical, functional and potency characteristics of type A botulinum toxin in clinical use. Botulinum J. 2008;1(1):153-166.
67. Dodd SL, Rowell BA, Vrabas IS, Arrowsmith RJ, Weatherill PJ. A comparison of the spread of three formulations of botulinum neurotoxin A as determined by effects on muscle function. Eur J Neurol. 1998;5(2):181-186.
68. Wohlfarth K, Müller C, Sassin I, Comes G, Grafe S. Neurophysiological double-blind trial of a botulinum neurotoxin type A free of complexing proteins. Clin Neuropharmacol. 2007;30(2):86-94.
69. Kukreja R, Chang TW, Cal S, et al. Immunological characterization of the subunits of type A botulinum neurotoxin and different components of its associated proteins. Toxicon. 2009;53(6):616-624.
70. Singh BR, Lopez T, Silvia MA. Immunological characterization of type A botulinum neurotoxin in its purified and complexed forms. Toxicon. 1996;34(2):267-275.
71. Sharma SK, Singh BR. Immunological properties of Hn-33 purified from type A Clostridium botulinum. J Nat Toxins. 2000;9(4):357-362.
72. Lange O, Bigalke H, Dengler R, Wegner F, deGroot M, Wohlfarth K. Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing? Clin Neuropharmacol. 2009;32(4):213-218.
73. Xeomin (incobotulinumtoxinA). Prescribing information. 2010. Available from: http://www.xeomin.com/files/Xeomin_PI.pdf. Accessed May 2, 2011.
74. Dressler D, Benecke R. Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil. 2007;29(23):1761-1768.
75. Borodic GE, Ferrante R, Pearce LB, Smith K. Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injection. Mov Disord. 1994;9(1):31-39.
76. Poewe W, Deuschl G, Nebe A, et al; German Dystonia Study Group. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport®. J Neurol Neurosurg Psychiatry. 1998;64(1):13-17.
77. Brashear A, Lew MF, Dykstra DD, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology. 1999;53(7):1439-1446.
78. ICH Q1A(R2) Guideline. Stability testing of new drug substances and products. 2003. Available from: http://www.fda.gov/downloads/ regulatoryinformation/guidances/ucm128204.pdf. Accessed Nov 3, 2011.
79. Grein S, Fink K. Complexing proteins are not required for stability of Botulinum neurotoxin type A preparations. Poster presented at: 71st Annual Assembly of the American Academy of Physical Medicine and Rehabilitation (AAPM&R); November 4-7, 2010; Seattle, WA. Poster P106.
80. Jost WH, Blümel J, Grafe S. Botulinum neurotoxin type A free of complexing proteins (XEOMIN®) in focal dystonia. Drugs. 2007;67(5):669-683.
81. Jost WH, Kohl A, Brinkmann S, Comes G. Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (Botox®) in healthy volunteers. J Neural Transm. 2005;112(7):905-913.
82. Benecke R. Xeomin in the treatment of cervical dystonia. Eur J Neurol. 2009;16 Suppl 2:S6-S10.
83. Consky ES, Lang AE. Clinical assessments of patients with cervical dystonia. In: Jankovic J, Hallett M, editors. Therapy with Botulinum Toxin. New York, NY: Marcel Dekker; 1994:211-237.
84. Comella CL, Jankovic J, Truong DD, Hanschmann A, Grafe S; on behalf of the US XEOMIN Cervical Dystonia Study Group. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci. 2011;308(1-2):103-109.
85. Botox (onabotulinumtoxinA). Prescribing information. 2010. Available from: http://www.allergan.com/assets/pdf/botox_pi.pdf. Accessed May 2, 2011.
86. Grafe S, Comella C, Jankovic J, Truong D, Hanschmann A. Efficacy and safety of NT 201 (botulinum neurotoxin type A free from complexing proteins) in treatment-naïve cervical dystonia patients [abstract]. Mov Disord. 2009;24(Suppl 1):S92-S93:Tu-401.
87. Grafe S, Comella C, Jankovic J, Truong D, Hanschmann A. Efficacy and safety of NT 201 (botulinum neurotoxin type A free from complexing proteins) in pre-treated cervical dystonia patients [abstract]. Mov Disord. 2009;24(Suppl 1):S92:Tu-400.
88. Grafe S, Hanschmann A. Safety and efficacy of repeated NT 201 (botulinum neurotoxin type A free from complexing proteins) injections of patients with cervical dystonia: a first long-term safety analysis [abstract]. Neurology. 2010;74(9 Suppl 2):A88:P01.270.
89. Roggenkämper P, Jost WH, Bihari K, Comes G, Grafe S; NT 201 Blepharospasm Study Team. Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm. 2006;113(3):303-312.
90. Wissel J, Müller J, Dressnandt J, et al. Management of spasticity associated pain with botulinum toxin A. J Pain Symptom Manage. 2000;20(1):44-49.
91. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry. 1976;33(6):766-771.
92. Wabbels B, Reichel G, Fulford-Smith A, Wright N, Roggenkämper P. Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm. J Neural Transm. 2011;118(2):233-239.
93. Jankovic J, Comella C, Hanschmann A, Grafe S. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-A randomized trial. Mov Disord. 2011;26(8):1521-1528.
94. Benecke R, Grafe S, Sassin I, Comes G. Overall clinical efficacy and overall tolerability of NT 201; botulinum neurotoxin free from complexing proteins [abstract]. Mov Disord. 2009;24(Suppl S1):S84:Mo-403.
95. Grafe S, Hanschmann A. Safety and efficacy of repeated NT 201 (botulinum neurotoxin type A free from complexing proteins) injections of patients with focal dystonia [abstract]. Neurology. 2010;74(9 Suppl 2):A87:P01.268.